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Naturally-occurring serine protease inhibitors of the Bowman-Birk family are of growing interest
due to their potential chemopreventive and/or therapeutic properties within the gastrointestinal tract
[1]. Recent studies have demonstrated a significant concentration- and time-dependent decrease
in the growth otlttZg human colon adenocarcinoma cells when treated with a mixture of soybean
Bowman-Birk inhibitors (BBl) [2]; such effect seems to be related to their intrinsic ability to inhibit
serine proteases [3]. ln this study, we have determined, in six commercial soymilks, the amounts of
total BBI and their major isoinhibitors, lBBl and IBBD2, in their active form. lBBl inhibits both
trypsin- and chymotrypsin-like proteases whereas IBBD2 inhibits trypsin only; despite showing
significant differences in their inhibitory properties, both exert anti-proliferative effects against colon
cancer cells [2]. By using cation exchange chromatography, the BBI isoinhibitors were isolated and
their specific trypsin inhibitory activity was used to estimate the amounts present in soymilks. lBBl
and IBBD2 concentrations ranged from 0.44 lo 5.20 and 0.27 Io 4.60 mg/100 ml of soymilk,
respectively; total BBl, considered as the sum of both isoinhibitors, ranged from 0.59 to 9.18
mg/100 ml of soymilk. These data show that physiologically relevant amounts of active BBI are
present in soymilk and may exert health- promoting effects. Further studies addressing the
protective effect of BBI to digestion on other bioactive compounds present in soymilk, with
particular emphasis on lunasin [4], are currently underway.
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